Close

BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. GM


Go back to BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia
(NASDAQ: BYSI) Delayed: 2.43 +0.14 (6.11%)
Previous Close $2.29    52 Week High $ 
Open $2.29    52 Week Low $ 
Day High $2.50    P/E N/A 
Day Low $2.24    EPS $ 
Volume 97,173